LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

97.31 0.18

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

94.55

Massimo

97.83

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.445 49.701
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 367M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+12.15% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-31M 19B
Apertura precedente	97.13
Chiusura precedente	97.31

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

59.52 / 62.66 Supporto e resistenza

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mag 2026, 16:49 UTC

Utili

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mag 2026, 16:26 UTC

I principali Market Mover

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mag 2026, 23:55 UTC

Utili

Lenovo Group Fourth-Quarter Net Soars on Strong AI Demand

21 mag 2026, 23:51 UTC

Discorsi di Mercato

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mag 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mag 2026, 21:53 UTC

Utili

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mag 2026, 21:02 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mag 2026, 20:55 UTC

Utili

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mag 2026, 20:30 UTC

Azioni calde

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Adj EPS 3c >BULL

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Rev $159.9M >BULL

21 mag 2026, 20:18 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mag 2026, 20:18 UTC

Utili

Webull 1Q Loss/Shr 4c

21 mag 2026, 19:43 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mag 2026, 18:58 UTC

Utili

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mag 2026, 18:15 UTC

Discorsi di Mercato

Gold Higher For Second Consecutive Day -- Market Talk

21 mag 2026, 17:40 UTC

Discorsi di Mercato

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mag 2026, 17:04 UTC

Discorsi di Mercato

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mag 2026, 17:01 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Stellantis Targets Distant but Constructive -- Market Talk

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

12.15% in crescita

Previsioni per 12 mesi

Media 108.88 USD 12.15%

Alto 135 USD

Basso 75 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

Bullish events outweigh bearish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation